维奈克拉在治疗血液系统恶性肿瘤中的研究进展  

Research Progress of Venetoclax in the Treatment of HematologicMalignancies

作　　者：徐斌 张晶晶 黄玉[2] 黄倩[2] 王海燕[2] 杨春燕[2] 贾路 吕琳琳 李颖[2] 王健 宋东晓[2] 张颢[2] 

机构地区：[1]济宁医学院临床医学院,山东 济宁 [2]济宁医学院附属医院血液科,山东 济宁

出　　处：《临床医学进展》2023年第3期3796-3802,共7页Advances in Clinical Medicine

摘　　要：细胞凋亡在恶性肿瘤的发生中起中心作用,恶性肿瘤细胞对凋亡的抵抗限制了传统细胞毒性治疗的疗效。B细胞淋巴瘤因子2 (B-cell lymphoma-2, BCL-2)蛋白家族是调控细胞凋亡内源性途径的关键因子。维奈克拉(Venetoclax, ABT-199)作为第一个上市的BCL-2选择性抑制剂,主要用于治疗急性髓系白血病(Acute Myeloid Leukemia, AML)和慢性淋巴细胞白血病(Chronic Lymphocytic Leukemia, CLL),同时正在其他血液系统恶性肿瘤中开展的临床试验也显示出其良好的抗肿瘤特性。本文主要对BCL-2选择性抑制剂的作用机制以及目前维奈克拉在血液系统恶性肿瘤中发挥靶向治疗作用的临床数据进行总结与概述,旨在为未来维奈克拉的更进一步应用提供一定的参考依据。Apoptosis plays a central role in the development of malignant tumors, and the resistance of ma-lignant tumor cells to apoptosis limits the efficacy of traditional cytotoxic therapy. The B-cell lymphoma-2 (BCL-2) protein family is a new and vital member of the endogenous apoptosis path-way. Venetoclax (ABT-199), the first BCL-2 selective inhibitor to be marketed, is primarily used for the treatment of acute myeloid leukemia (AML) and chronic lymphocytic leukemia (CLL), while it is also being evaluated in clinical trials for the treatment of other hematologic malignancies. This arti-cle summarizes and details the mechanism of action of BCL-2 selective inhibitors as well as existing clinical data on the targeted therapeutic effects of Venetoclax in hematologic malignancies in order to serve as a reference for future Venetoclax applications.

关 键 词：BCL-2 维奈克拉 血液系统恶性肿瘤 靶向治疗 

分 类 号：R73[医药卫生—肿瘤]